DIAGNOS and the CHUM are launching the testing phase of autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening
May 26 2022 - 9:58AM
Diagnos Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce, in partnership with the
Centre hospitalier de l’Université de Montréal (CHUM), the launch
of the testing phase for autonomous artificial intelligence
solutions dedicated to diabetic retinopathy screening.
It is with great pleasure that DIAGNOS and the
CHUM are launching the clinical study which will make it possible
to establish, with precision, the level of performance of the
autonomous algorithms utilized for the identification of the
disease and its classification by level of severity, with patients
suffering from diabetic retinopathy.
“This phase marks the beginning of the final
step of this partnership aiming for the automated detection of
diabetic retinopathy, which began in June 2018,” says Mr.
André Larente, President of DIAGNOS. "This stage of
testing and performance analysis was approved by the CHUM,
following the positive results obtained over the past few months by
CHUM clinicians as part of the rigorous independent evaluation
process applied to analyze the performance of the classification
algorithms by level of severity run in autonomous mode. »
“This project is well aligned with the CHUM's
desire to improve accessibility of its services to the patients
through partnerships that nurture the development and integration
of innovative solutions.” said Dr. Fabrice Brunet,
President and CEO of the CHUM.
The retinal fundus images of more than 600
diabetic patients from the CHUM's endocrinology Department will be
analyzed by the NeoRetina artificial intelligence algorithm of deep
learning from DIAGNOS in collaboration with the CHUM's
ophthalmology Department. This solution makes possible the
identification of lesions caused by diabetic retinopathy and the
classification of the evolution of the disease by level of
severity. Performed in a “double-blind” comparison mode, this test
will allow the CHUM professionals to precisely establish the level
of performance and precision of the NeoRetina autonomous
algorithms.
As for the benefits provided by this automated
screening technology, the Head of the endocrinology
Department at the CHUM, Dr. Andrée Boucher, is delighted
with the increased volume of screenings that can be performed:
“Diabetic retinopathy affects a good number of diabetic patients.
However, considering that in the initial stages of the disease,
patients are generally asymptomatic, and symptoms often only appear
at the more advanced stages of the disease, this means of
independent screening, easily carried out at the time of the annual
examination of the patients, will allow us to reduce the number of
complications that can lead to blindness. »
Dr. Salim Lahoud, Head of the CHUM's
ophthalmology Department, agrees with his colleague and
affirms that the screening for diabetic retinopathy carried out
using the artificial intelligence solutions developed by DIAGNOS
will contribute to prioritizing and improving the speed of patient
care by the ophthalmologists of his department. In addition to
being accurate, efficient, and swift, DIAGNOS' artificial
intelligence screening solutions permit a significant reduction of
the costs and the early identification of pathologies. Diabetes
being the second leading cause of blindness in Canada, the
integration of these solutions into medical follow-up programs,
such as those offered to diabetic patients, will allow numerous
patients to preserve their sight!
About Centre hospitalier de l’Université de
Montréal (CHUM)The Centre hospitalier de l’Université de Montréal
is an innovative hospital devoted to serving patients. It provides
the highest quality specialized and ultraspecialized care to
patients and the general public all over Québec. Through its unique
expertise and innovations, its aim is to improve the health of the
adult and aging population. As the Université de Montréal hospital,
CHUM is dedicated to care, research, teaching, health promotion,
and the assessment of technology and health intervention methods in
order to continually improve the quality of care and the health of
the population. Since fall 2017, patients and their families have
been able to enjoy a renewed hospital experience at CHUM's new
facilities.
Additional information is available at:
www.chumontreal.qc.ca
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: alarente@diagnos.ca
Andrée-Anne Toussaint
Centre hospitalier de l’Université de Montréal (CHUM)
Tel: 514 890-8000, ext. 23675
Email: andree-anne.toussaint.chum@ssss.gouv.qc.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024